To review the literature to identify factors affecting haematuria assessment in bladder cancer.
Introduction
Bladder cancer is one of the most common cancers, with an estimated 76 960 new cases and 16 390 deaths from the disease in the USA in 2016 [1] . Patients with bladder cancer typically present with haematuria [2] , whether it be macroscopic or microscopic in nature. The most common symptom is macroscopic haematuria, occurring in~80% of patients [3] . As such, clinical guidelines recommend appropriate evaluation of haematuria, with investigations such as urine microscopy/culture/sensitivities (MCS), urine cytology and radiological imaging, as well as expedient referral for urological assessment with a view to cystoscopy [4] [5] [6] [7] .
However, only 15.0-19.3% of patients with macroscopic haematuria and 4.0-4.8% of patients with microscopic haematuria have underlying bladder cancer [3, 8] . A further 0.9-3.6% and 0.3-0.5% of macroscopic and microscopic haematuria cases, respectively, have underlying renal malignancy [3, 8] . Thus, the vast majority of haematuria occurrences are due to comparatively benign aetiologies such as UTI or BPH, or may have no identifiable cause despite thorough investigation [3, 8] . As such, many primary care physicians may be reluctant to over-investigate their patients, given the unlikely diagnosis of cancer. This may explain why some patients experience significant delays between their initial primary care consultation and subsequent referral to urology [9] .
Delays in the diagnosis and treatment of bladder cancer are associated with poorer outcomes [2, 10] , highlighting the importance of timely haematuria assessment. The time between haematuria recognition and bladder cancer diagnosis can be considered in multiple stages, from haematuria onset to initial medical consultation, through to urology referral, consultation and ultimately completion of investigations. There may be factors that affect how quickly patients are able to progress through each stage and how thoroughly they are evaluated.
We aimed to systematically review the available literature and identify factors associated with sub-optimal haematuria assessment.
Methods
A systematic review was performed in accordance with the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [11, 12] . The scientific literature databases EMBASE and Medline (PubMed) were searched systematically in March 2016 using the keywords 'hematuria', 'urinary bladder neoplasm(s)' and 'bladder tumor'. The search and study selection were performed by two independent assessors (B.N. and S.S.). Studies evaluating the timeliness and adequacy of haematuria assessment, in the context of bladder cancer, were assessed for inclusion by two authors (B.N. and S.S.). A broad search strategy with no limits applied was adopted to avoid missing relevant articles due to potential keyword or coding errors in the databases used. Additional articles were identified through manually searching reference lists of relevant retrieved articles. Exclusion criteria included age <18 years, animal studies, and non-English articles. Editorials, correspondences, review articles, conference abstracts and short reports were also excluded. No sample-size limitations were applied.
All studies were appraised using a modified version of the Critical Appraisal Skills Programme (CASP) checklist for cohort studies [13] .
Results
Following the systematic search, 6 799 articles were retrieved. From this, 2 170 duplicates were removed and 4 605 were deemed not relevant. Following our screening process, 17 studies published between 1983 and 2015 were deemed suitable for inclusion in our analysis, which comprised 11 retrospective and five prospective cohort studies, and one cross-sectional survey. An outline of the study selection according to the PRISMA guidelines is provided (Fig. 1) . Characteristics of selected articles are summarised in Table 1 [9, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Significant variations in methodologies, definitions and outcome measures precluded formal meta-analysis.
Quality appraisal of the 17 included studies was performed using the modified CASP tool (Fig. 2) [9, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . In summary, most of the included articles had acceptable methodology pertaining to patient recruitment, exposure and outcome measurement. Outcome measurement was deemed at high risk of bias in studies where questionnaire and recall data were used. Application of results to the local population was deemed poor in studies where questionnaire response rates were low, predisposing to selection bias.
Discussion

Timeliness of Haematuria Assessment
Eight studies reported factors impacting on the timeliness of haematuria assessment [9, [14] [15] [16] [17] [18] [19] [20] , which were gender, age, smoking, degree of haematuria, and socioeconomic status (SES). All eight articles commented on gender, five of which associated female gender with greater delays in evaluation [14, 15, [17] [18] [19] , one demonstrating both males and females experience delays at various intervals [9] and two showing no difference [20, 21] . In particular, women wait longer than men for urological review [9, 15, 19] and bladder cancer diagnosis [14, 17, 18] . Four publications addressed age, with mixed findings [14, 15, 17, 20] . Studies addressing smoking [20] , degree of haematuria [20] and SES [15] were limited. Relevant findings are summarised in Table 2 [9, 14, 15, [17] [18] [19] [20] [21] .
Gender
Although the incidence of bladder cancer in males is three times that of females [30] , females consistently present with more advanced-stage disease at the time of diagnosis [31] and have poorer prognosis, even after controlling for disease factors [32] . Gender disparities in the timeliness of haematuria evaluation may help to explain such a discrepancy. Several small and early studies reported conflicting results, identifying no difference between genders [17] or greater assessment delays with males [9] . However, more recent and large-volume studies have shown an association between female gender and delayed haematuria evaluation.
Garg et al. [15] used the Surveillance, Epidemiology and End Results (SEER) public cancer registry data in 35 646 American patients aged ≥66 years with a claim for haematuria within 1 year preceding bladder cancer diagnosis. In this study, women were referred later to see a urologist after their index haematuria claim, waiting a median of 6 days compared with 2 days for men. Controlling for demographic and disease factors, women still had a longer time-to-urological review (hazard ratio [HR] 0.90, 95% CI 0.87-0.92; P < 0.001). Women were also more likely to experience delays in evaluation with cystoscopy, upper tract imaging, and urine cytology (odds ratio [OR] 1.12, 95% CI 1.05-1.20; P < 0.001). Further data from the SEER database identified that women had greater delays from initial haematuria or UTI claim to bladder cancer diagnosis, with mean wait times of 72.2 days vs 58.9 days for men (P < 0.001) [18] . A subsequent high-volume series assessing patients aged <65 years seen in the private healthcare setting also supported the SEER-Medicare findings [14] .
Despite all of this, a major limitation with these studies is their inability to consistently differentiate between macroscopic and microscopic haematuria, the importance of which is highlighted by variations in clinical decision-making, with macroscopic haematuria warranting more urgent assessment. Moreover, it remains unclear why women experience greater delays. Previous studies have shown that women are more likely to undergo UTI management during their bladder cancer evaluation [14, 18, 21, 22] , which may contribute at least in part to these delays.
Age
The incidence of bladder cancer increases with age [30] and several studies have assessed the effect of age in regards to evaluation of haematuria, with varied results. The Swedish Mansson et al. [17] study identified that patients aged ≥70 years had greater delays from initial medical consultation to bladder cancer diagnosis (69 vs 54 days, P < 0.01). However, several other studies have reported no consistent differences with varying age [14, 15, 20] .
Smoking
Only one study had addressed smoking as a risk factor for delayed haematuria assessment and no difference was found between smokers and non-smokers [20] . 
Degree of haematuria
Wallace et al. [20] reported that patients with macroscopic haematuria had shorter wait times between urology referral and urology consultation (P < 0.001). Similarly, Cohn et al. [14] identified that patients with macroscopic haematuria were less likely to have a delay between their initial haematuria claim and bladder cancer claim.
Socioeconomic status
Literature regarding the effect of SES on haematuria assessment is sparse. Many studies acknowledge limitations in the adequacy of SES data, with a view that such information is particularly important where access to healthcare is dependent on income. Garg et al. [15] collected information on the median income of their American patients and stratified them according to quartile. Although the authors did not elaborate on the result in their discussion, patients in the highest income quartile had reduced time-to-urological review compared with those in the lowest income quartile (HR 1.07, 95% CI 1.03-1.10; P = 0.001).
Adequacy of Haematuria Assessment
In all, 14 studies reported outcomes on the thoroughness of haematuria evaluation [14] [15] [16] [17] [18] [21] [22] [23] [24] [25] [26] [27] [28] [29] , with 12 articles commenting on gender [14] [15] [16] 18, [21] [22] [23] [24] [25] [26] [27] 29] , indicating that women experience inadequate or inappropriate haematuria evaluation. Specifically, women are less likely than men to be referred to urology (two studies) [23, 27] , receive imaging (three studies) [14, 23, 25] , and be investigated with cystoscopy (two studies) [15, 25] . In addition, four publications found that women are more likely to be managed for UTI [14, 18, 21, 22] and three studies found that women are more likely to undergo three or more prereferral primary care consultations during their evaluation [16, 22, 26] . Six studies discussed the effect of age [16, [23] [24] [25] 27, 29] , with advancing age associated with more comprehensive assessment overall. Smoking [23] [24] [25] and degree of haematuria [23, 28, 29] were addressed by three studies each, suggesting that smokers and those with microscopic haematuria undergo less thorough assessment. Relevant findings are summarised in Table 3 [14, 15, 17, 18, [23] [24] [25] [27] [28] [29] .
Gender
Referral to urology is important for patients with haematuria, particularly for investigation with cystoscopy. Some small studies have shown no significant gender differences in referral rates [17, 29] . However, Buteau et al. [23] identified that only 13.6% of women were referred compared with 40.2% of men (P < 0.001), findings which were corroborated In addition, three recent high-volume series have associated female gender with a significantly lesser likelihood of undergoing upper tract imaging, cystoscopy or both compared with males [14, 15, 25] . Moreover, one study reported that only 20.7% of women were sent for imaging compared with 80% of men (P = 0.001) [23] .
Additionally, several studies have found that women undergo more GP consultations prior to urology referral. Lyratzopoulos et al. [26] identified that preceding their bladder cancer diagnosis, women were more likely to have three or more pre-referral consultations than men (OR 2.31, 95% CI 1.98-2.69). Subsequent research by the same group corroborated their initial findings, with 27% of women vs 11% of men undergoing three or more pre-referral consultations preceding diagnosis (P < 0.001) [16] . Several other studies have reported similar results [19, 22] . It is unclear why women experience more pre-referral consultations. Previous research has shown that females are more likely to be managed for UTI during their evaluation [14, 18, 21, 22] and this may account for some of these additional GP consultations.
Age
Johnson et al. [27] identified that patients of advancing age had higher rates of referral to urology than patients aged <40 years (P < 0.001). However, their study did not discern patients' degree of haematuria. It is possible that a greater proportion of older patients had macroscopic haematuria, providing greater imperative for urological referral. Conversely, two studies have reported no association between age and referral to urology, irrespective of the degree of haematuria [23, 29] . For completeness of assessment, a large retrospective cohort study of 2 455 American patients aged ≥40 years showed that older patients were more likely to receive cystoscopy and imaging (OR 1.03, 95% CI 1.01-1.05; P = 0.014) [25] . In contrast, Shinagare et al. [29] , whose retrospective study stratified 100 American patients into age <40 years and age ≥40 years, found no difference in the receipt of imaging, urine cytology or cystoscopy between the age groups. The overall impression is that age is not consistently associated with differences in haematuria assessment.
Smoking
Smoking is a strong risk factor for bladder cancer [33] and clinical guidelines on haematuria recommend thorough evaluation of patients with a history of smoking [4, 34] . Buteau et al. [23] appraised the adequacy of haematuria assessment among primary care physicians and found no difference in urology referral rates between smokers and nonsmokers. Friedlander et al. [25] further reported that a positive smoking history had no effect on the likelihood of receiving imaging or cystoscopy. Conversely, Elias et al. [24] assessed 1 502 American patients who were deemed at high risk of developing bladder cancer and identified that smoking was associated with an increased likelihood of having no cystoscopy (OR 3.84, 95% CI 1.06-14.3; P = 0.04) and no cystoscopy with imaging (OR 2.43, 95% CI 1.12-5.26; P = 0.025). In summary, smokers appear to be no more, or perhaps even less likely to undergo comprehensive investigation. Further research assessing this demographic is required.
Degree of haematuria
Given that up to 15.0-19.3% of patients with macroscopic haematuria have underlying bladder cancer [3, 8] , thorough assessment of patients is important and automatic referral to urology is recommended [4] [5] [6] [7] . Buteau et al. [23] reported that only 40.6% of patients with macroscopic haematuria and 14.5% of patients with microscopic haematuria were referred Aziz et al. [21] Buteau et al. [23] Cohn et al. [14] Elias et al. [24] Friedlander et al. [25] Garg et al. [15] Henning et al. [22] Johnson et al. [27] Lyratzopoulos et al. [16] Lyratzopoulos et al. [26] Mansson et al. [17] Mommsen et al. [9] Nieder et al. [28] Richards et al. [18] Santos et al. [19] Shinagare et al. [29] Wallace et al. [20] Did the study address a clearly focussed issue?
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14 © 2017 The Authors BJU International © 2017 BJU International to urology (P < 0.001). Shinagare et al. [29] focussed on doctors' adherence to the 2001 AUA haematuria guidelines [34] and found that 51% of patients presenting with macroscopic haematuria had imaging vs 24% of patients with microscopic haematuria (P = 0.009). Additionally, Nieder et al. [28] surveyed primary care physicians in the USA and found that only 69-77% referred their patients with macroscopic haematuria to urology. Guidelines are devised to aid decision-making and encourage consistent standards of care. However, it can be difficult to balance guideline adherence with clinical acumen. Improved clinician education may be required to encourage consistent, evidence-based haematuria assessment.
Anticoagulation
Anticoagulation therapy within the therapeutic range has been shown not to predispose patients to haematuria [35] . In the context of haematuria, clinical guidelines stress the importance of managing anticoagulated patients no differently to patients without anticoagulation [36] . Up to 24% of anticoagulated patients with macroscopic haematuria have an underlying urinary tract tumour [37] , a similar incidence compared with previously studied populations [3, 8] .
Friedlander et al. [25] reported an association between anticoagulant use and receipt of imaging (OR 1.72, 95% CI 1.06-2.78), but not with cystoscopy. Further research is required to clarify the effect of anticoagulation on haematuria evaluation.
Implications and Future Directions
To address the disparities in haematuria assessment and mitigate associated adverse outcomes, more targeted education of primary care practitioners is needed. In Australia, there is currently a lack of credible, evidence-based haematuria guidelines. The difficulty experienced by clinicians in managing their patients with haematuria is further compounded by inconsistent guidelines worldwide. The USANZ is the foremost urological body in Australia. At the local level, it may be constructive for the USANZ to take a lead in improving knowledge of urological issues, both within healthcare and more broadly. It is crucial for societies like the USANZ to provide medical practitioners and the general population with trusted resources to improve knowledge and awareness [38] , with the formulation of reputable haematuria guidelines an important first step. From here, better training of urologists may also be required to improve consistency with haematuria assessment. Rashid et al. [39] reported that patient simulation can augment pre-and peri-operative skills in urology training. In combination with improved education at the primary care and public level, a multi-faceted approach may benefit healthcare providers in managing haematuria more confidently and appropriately.
A recent study suggests that disparities in the evaluation of haematuria also exist among Australian patients and that greater consistency is required [40] . However, whether it is appropriate to follow through with surgery on all patients with bladder cancer is contentious, particularly in the elderly. A multicentre study by Izquierdo et al. [41] identified that cystectomy for the treatment of bladder cancer in patients aged >80 years is relatively safe, with early complication rates comparable to younger patients. It is promising that aggressive surgical intervention appears appropriate should evaluation of haematuria reveal underlying malignancy.
Conclusion
Haematuria is a non-specific clinical feature and in most cases the underlying cause is benign or idiopathic. However, timely and appropriate evaluation remains important to enable expedient diagnosis of serious pathology in a small proportion of patients.
The present study has identified several factors that impact on the timeliness and adequacy of haematuria assessment. Female gender is associated with sub-optimal haematuria assessment. Not surprisingly, patients with macroscopic haematuria are evaluated more promptly and thoroughly than those with microscopic haematuria. Paradoxically, smokers appear less likely to undergo thorough assessment despite being at increased risk of both bladder and renal cancers. Further research is required to elucidate the impact of age, SES and anticoagulation status on haematuria evaluation.
Our systematic review has some limitations. Due to heterogeneous measurement outcomes, meta-analysis could not be conducted. Moreover, many studies lacked multivariate analysis. As a result, it is difficult to establish whether some factors are truly independent predictors of delayed or inadequate haematuria assessment. Nonetheless, it is concerning that some patients experience sub-optimal haematuria evaluation. This may be addressed through appropriate education of clinicians and the wider public, as well as provision of reputable local guidelines on haematuria.
